Earnings call transcript Q3 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, and thank you for standing by. Welcome to the Rhythm Pharmaceuticals Third Quarter 2022 Earnings Conference Call. [Operator Instructions]

I would now like to hand the conference over to your speaker today, Dave Connolly, Investor Relations and Corporate Communications at Rhythm Pharmaceuticals. Please go ahead.

David Connolly

morning, good and you, everybody. Thank IR I'm Rhythm. Communications at Corporate Dave Connolly, here and

For conference release business the available via can participating we results our those you of and This ir.rhythmtx.com. the our the page and our morning, on third by website financial at on a be controlled is call, provides going update, section to press which investors had Investors website. of that accessed slides our quarter

in X us Chief our Slide of the here International Chien, on Boston listed Mazabraud, on me Meeker, and for Hunter Chief line call with President Executive France. as Yann of and Executive is the Executive David are Smith, from And Officer; North America; Head conference President today Vice Head Jennifer joining Financial Vice Chair, President, Officer; and

I'll With you including a statements from in future report most statements these contains expectations, constitute remarks our those results forward-looking and call on those may quarterly concerning annual this forward-looking important prospects, recent the factors, differ of materially SEC. various with which by actual Slide plans file or discussed X, indicated result remind as

relied views of We any our as addition, represent not any obligation views upon disclaim as statements. specifically our be as and such In representing of statements any should dates. only forward-looking today subsequent update to

to will on begin who call David, With that, turn over the I'll Slide X.

David Meeker

thank our you Dave, joining quarter and you, call. morning, for everyone, Thank and good earnings third

number and is identification. disease, in nature patients facilitates rare commercial of of syndromic both really briefly the call, the the quarter. today potentially both in the launches II good our hypothalamic terms obesity the we we So of that will and Last treatment with is we Phase on but the needing Europe. progress a of full BBS data we week, today's had are and U.S. focus on really data disease presented opportunity, real which strong a set, the making review patient

Fundamental the been today we walk get whether here. about we this good work, as can signals about system August early better has and to felt signals you even question in those we and we feel

since prescriptions physicians patients Country-specific approved Europe, X, some will these. XX-plus approval and we our go we in have EC scripts, provide written Yann for early authorization have the Slide received BBS depth France. for have in followed on XX-plus multiple record BBS, in course, from access update. with reimbursement. expansion. we XXX-plus happening been received for launches On Jennifer the with was June, approval of will into are which programs the label progress in continue program to clinical development, opportunity international time In for significant all

X. Slide

BBC So we Improve TOS the examples in are we which a with good presence meeting Berlin had meeting, at Society our and should strong at how both of this presentations, XX presence hosted work.

In intensely addition meeting lead the individual with focused science. understanding to on we needs, the to want and being patients'

III for would is be patients continues for reduction the approved approximately with program testing will body be reservation our sustained fat loss is more At the Tos in We In an treating therapy showing becomes the disease deficiencies leaders or X% reduction that acceleration LEPR and relative and diseases M&A composition is support showing the of largely understanding. setmelanotide. data and about the when are effect the the want Phase due rare the POMC there the gene the both mass patients learn where to be genetics, positive of INSIVRI trial. continue impact to and available, we a effort. to of we awareness in data in We the observation on diseases, either first BMI with that BMI eligible to presented disease patient that of genetic

X. Slide

health the briefly So XX,XXX to or the obesity patients we followed system are patients larger by our now be care believe that current may hypothalamic than difference and opportunity the with have being identified, these let although similar population, for primary actively part, commercial review estimated somewhat This are population most the me is X,XXX for they engagement of endoprinologists, BBS program, acquired point them. call efforts. for a ongoing fundamental transformational patient is the our a

met on Mean the for in decreased their BMI at or or BMI we some all XX% during was at decrease more point XX which decrease BMI of XX X, week, the patients, near last their the by primary of weeks. So by results X% Slide announced point XX.X%. more 'XX end XX trial. XX XX XX-week

As you of the slide, the BMI the quite of in next remarkable. can magnitude see the think we response addition to decrease, is on consistency the

So Slide X. this is

So purple had plot who decreased patients highlighting on the week, last waterfall weeks. not XX focused on at BMI we X the the by XX% more box, or the

box. losing slowly and which through lose but therapeutic gain, continued but location. retitrate weight. that XX% there XX in allow and lose dose was regained the to more the weight noncompliant, XX% compliant they we last that showed, then was since the either patient the approximately when were the has lower dose That's was the patient rapid dose was reach They patients patients left-hand course That who, having has as to patient This period only patient, XX% the the two reverse weeks. steadily Ross of us as In side failed to due the been increased AEs. Dr. has now who either again X% one the reached on were and did were on patients short, was the decreased or lost they discontinue you, box remind or once escalation right. to drug more dose was first when on time To track been at

the of patients XX long-term on extension. BMI this BMI visit and a of highly supportive we and their five acquired strong, In decreased as durable with data therapy, the visit population have of XX mean consistent of reaching heterogeneous in second this their XX.X% HO. It's reached patients their by Slide effect XX. a see first XX in weeks who had decrease summary, XX.X%. patients

Slide positive a with pleased here. alignment and We're C Type have reached the obesity. FDA III and trial breakthrough program to XX. to hypothalamic have Phase acquired meeting which diagrammed on designation our We received the for is design, had

will will at X:X We X-week primary followed the to an by dose. randomized titration The patients their weeks. in XX or XXX enroll BMI period placebo with at endpoint treatment XX change weeks dose be therapeutic

look here, those on you updating summarize XX, our ongoing forward we efforts Slide clinical to and XXXX. further we programs, On multiple in

over will Jennifer. call to I And with that, turn the

Jennifer Chien

David. you, Thank

ancillary we two we and pleased the of BBS very on to the are June to BBS our commercial physicians, patients. second launch September metrics just the Today, XX the continue community, with including by close approval of We BBS, course, you, share quarter. remaining plan and, that in execute cumulative in some received payers XX, are our across just the on third quarter. through I'll we weeks reception remind

last the earnings will covered of report the in BBS metrics call, our numbers July initial included weeks be shared some we first metrics through we On Those today. the six XX. launch, which

that start for we impact Slide physicians and Once dialogue cause a recognize on we to insurance the transition the educating and educate journey, made, and results hasn't prescription, on MCXR XX. a All we outlines to further Once therapy outlining So physicians are provide help to pathway itself, the let's restoring the at by approved This to and as and in Early the experience go symptoms journey physicians. this patients benefits them BBS only patients accurate with an are diagnosis decision the to made, this get and patients opportunity onset on obesity from on aimed we is ahead the signaling. in root This targets on a is on a impaired patients with treat. with IMCIVREE engage support slide driving IMCIVREE signaling. that disease they treat early as Imcivree. of diagnosis. MCX secure to the on hyperphagia decision that coverage to drug

Next slide.

our with are in quarter full These XX. launch numbers first results from through very are BBS. We September pleased cumulative

patients, approval XX from are We have nation. XXX-plus prescriptions distributor the these across and received are XXX that for than of physicians coming BBS prescriptions, prescribing these we importantly, over more unique And IMCIVREE for pleased BBS we launch for in than more from launches and received here. reimbursement for of have already still difficult rare the early XX to disease are even these. is project It or predict

to early interactions full for support around identification, with pleased we helping However, and patient the quarter system we payers with and diagnosis customer results is education and are working. treatment are engagement the as first

prescribers to called the to Patient and second #X providers is move who along success I is the are territory a our This XX-plus into is of and both our managers healthcare prescription. not patients, specialty accounting of ongoing the the engagement for promotion targeting the speaks prescribers and XX% receipt to these Rhythm new our for not accounting Association prescribers. Pediatricians of little with Of of XX% the is prescribers, endocrinologists, so next non-personal on go XX% efforts adult Interestingly, were Let's prior by with and surprising. BBS of slide, can more which on pediatric detail to prescribing. community.

slide. Next

continue as date on received the encouraged well payer mix to be coverage to decision. We as early by the prescriptions

of commercial the are prescription. Medicare are X% break by and by are plan. we prescriptions total mix Here, payer plans. federal on down the a XX% XX% Medicaid, of X% covered

stages, Additionally, work of initial typically first prior our appeal are secure with approvals months. the in teams three more to continue one and authorization reimbursement. in to vast to hand, remaining majority benefit This between than the process verification, prescriptions for takes reimbursement the or XX

Others commercial the approval, new plans state. with take our we post updated review FDA-approved rare language within periods indication aligned pleased with four indications a will are months typical states to A label. new policies Medicaid, commercial disease to BBS to vary average, on XX six months. see few plus months. by While On review to eight can drugs in six review for first come start

are some policies. sitting With exclusion. states in starting which states to are obesity IMCIVREE, of is favorable IMCIVREE are There some also we see that excluding

we in appeals through positive do process. see on basis even a these an reimbursement However, states, case-by-case

jab. we are we appeal, unable coverage. have those the for patients all more confident our this we We assistant free for appeals For continue on and coverage IMCIVREE options these developed at for program pursue Medicare we reimbursement or of patients, time, we process. exhausted levels to to including that reimbursed are have to patient Even gain see will therapy policies remain due patients, through our

More Moving the have the numbers Children of prescription. patients patients from slide. and in characteristics than clinical received XX% with patient for them prescriptions have patient of in range XX%. include support We than age transitioned see trials. older access, our help prescriptions to IMCIVREE adolescents on that more XX and XX% BBS almost of program, ongoing account XX to treatment participate adult us we of These initiate the and account Rhythm for the service patients to have prepare next we continuity whom and consented for ensure patients enabling InTune, to therapy. achieve

team, their our positive with with engage the provided. therapy patients on feedback these InTune As and experience support we on hear support

Next slide.

As and you hungry less her XX patient quote that is has the highlighted one from daughter pounds. had see lost more energy

is more wonderful education here, effects on family with through of day. benefits a to noticeable to night, we IMCIVREE food craving boy educate behaviors expectations was the stage be on see manager, and hunger And to InTune an able side during confidence. a to Another change better call IMCIVREE, able one so sleeping then in on them titration to at able at lastly, change smiling PEMs, new manage from patient they was the found after potential how we experience decreased to the due were Separately, being school. set the

families. IMCIVREE positive pleased We difference are and these patients hear so making to is that to a

slide. Next

BBS We opportunity our launch, there as we more still physicians growth patients. with have diagnosed had a is strong and start identify for additional continue to on

have patients main buckets. We segmented with four BBS into

that physicians educate. care Rhythm we to First, there under the of known engage to already are and continue patients

we of that through our Second, discover the there of field under patients teams. diagnosed the care physicians are already work new

diagnosis. is suspect where BBS, efforts their of having Third, patients an applying inform patients in may to our can answer testing physicians undiagnosed availability their there diagnostics. which journey find genetic fourth, help of help And the to group, who are the largest

they For the a each field efforts educate multichannel to to targeted broader patients a the our are of of segment, so of a providers and treatment diagnosis to of a team aware approach supplement IMCIVREE group leverage as healthcare get option. we the and can availability quicker

international region. an provide me the progress in With to Yann hand over to that, update let it the on

Yann Mazabraud

Thank I and with morning, is Europe for start been Slide dynamic Jennifer, that IMCIVREE, testing region. of a Center quick thanks leading already patients important and genetic and an deficiencies you, market Syndrome quarter good the will everyone. to a again reminder XX both very to Disease patients for many Bardet-Biedl advanced has the It capabilities, European with and Excellence Rare LEPR identified. POMC more many international with

For X,XXX receiving estimated have patients, POMC, diagnosed is already the care. PCSKX and patients identified prevalence about to European and LEPR we and patients, XXX XXX

care Bardet-Biedl European are For to be know and are Syndrome, X,XXX plus than EUX diagnosed patients estimated the UK. in is that patients, approximately and prevalence there who receiving X,XXX we more

XX. Slide

do you Regarding can ago, tremendous in securing the and progress we made in Sadaf PCSKX of A enjoy influential UK. IMCIVREE the we on the is recognized launch obesity our the as have UK, the Cambridge European we genetic LEPR from about launched in who leading POMC, from first like left for support leaders obesity most prescriptions. and of Farooqi who see weeks experts obesities, few treated one Professor as deficiency the access And widely in slide, Europe.

are and France Germany. in in IMCIVREE able in to we to Now the UK, patients deliver

and We Italy in in also soon year very Netherlands, are and the in on Israel end of by Argentina in track and launch the XXXX. Spain, in Sweden to this

XX. Slide

patients Syndrome significantly for Europe, IMCIVREE reduce with final in beginning Commission We deliver to authorization that we received weight. European and who September. the body Regarding looking in are Bardet-Biedl the precision hunger to from are medicines can BBS.

and summer, said, innovative XX we and time. a therapeutic allows the just approval, which to have recommendation before approval Syndrome very positive France, a Bardet-Biedl there. the rare called committee, even Germany, As XXX France, CHP alternatives reimbursed a and early other David available. very access In recognized interaction following reimbursed balance risk-benefit is program achieved with specific in diagnosed With when over is the early so when APX we record the with far. again in announced EMEA a federal is, clear API patients access for the joint FDA we no as there need approximately therapies are and chemical with unmet GBA, the engaged positive days

XXXX. exclusion are the exemption Kingdom, to for reimbursement Germany are we the engaging In the As and POMCPCKXandLIPA, looking seeking the of we care authorities we also Spain did IMCIVREE we from Netherlands. half launching meantime, with forward lifestyle and Italy, in list, are in United drugs the first health in

evidence-based was it pathway are but Last helped diagnosis genetic NCX was with last we XX. support was first-ever It XXX improved Berlin, scientific meeting truly route hypertensvere as discussion. need turnout focused on therapeutics will and not care It obesity with treatment and on and Center engagement science to practices pathway-related the how There Slide how and integrate of XXXX. the the and and and that the nearly on move Chair has month, from disease. test the was by were we as unmet are planning Peter cochair. of Professor led least, of part in share and help to forward, care. meeting in scientists alliances did and pleased the international Habit we of and Hunter? the No who in University in in ideas already patient obesity to best called of Improve for field very the Berlin, old Martin meeting. address next for to practices doubt Kennan the people physicians It and Lasarte Medical level Professor

Hunter Smith

offering. in of offering Including Pro We XX. $XX well million of that hand greenshoe, from cash forma, hand, public with on Slide on million $XXX green capitalized exercise the from shoe put quarter proceeds partial additional in very our the $XXX cash this raised would in plus million. September. in to closed million Turning we $XXX the our

Importantly, some successfully our the expanded we base, biotechnology. investors and investor long-term by anchored in sophisticated deepened of most

remain received financing from in as IMCIVREE confidence for the IMCIVREE million for investment interest of during BBS, quarter ACR's June. our generate EC in sales Healthcare development an significant achievement Rhythm and agreement terms with $XX.X the concluded the per potential growth our Royalty execute our the BBS to provide In demonstrates XXXX. strong Authorization eligible indication. Marketing receive resources these with to addition, we the Partners into $XX and We milestones commercialization revenue following transactions additional this and global revenue million additional certain XXXX. in to financial on in Together, strategies extend and upon runway

start in third BBS from of start receipt the to access approximately patient $X.X growth a for sales early start following to since process the represented launch patient the written takes million a with months the one to quarter strong more our Revenues the PDUFA form we XXX represent XX, than physician. as expect June. Slide of scripts an a BBS On three

month reduced costs. previously were Ipsen additional once for These our patients addition, under initial sales. second due of the drug This agreement. during XX% of of R&D titration XX% shipment product the XX% the beginning quarter quarter subsequent reflected was the as schedule, for quarter million shipment of the R&D the of quarter In given is reduction the per month year-over-year sold The compared our a also quarterly from approximately basket, quarter the million paid than from to II studies. this the shipments. Phase expenses for by Cost in decrease was has million Phase II lower one increasing last decrease in to The second fewer milestones is over third $XXX,XXX, licensing to the represent year. in factors by well There Phase total $XX.X well year. or X% $XX revenue. switch original of renal driven primarily factors. $XX.X study was the for and These -- third decrease as activity in as phase completion costs. trial design to two $X.X goods was the the volume in the clinical studies. increased decrease shipment as Ipsen amendments on dose related largely This IMCIVREE formulation the decreases result royalty our costs of were $X.X amortization to costs de due open-label quarter-over-quarter to the revenues and as typical The BBS a decreased first of partially BBS from III, The approved, spending there. in approximately from a study million same first continuing and trial and CMC M&A, Daybreak QTC dose in to product clinical vials extension includes million offset weekly XX% to the and volume were of patient initial novo of on shipment two

primarily in expenses sequencing Gene I'm million year the to $XX.X quarter. -- $X.X the expenses million the sorry, as commercial in for quarter the organizations. quarter by decreased this increases third as increased BBS million were international same slightly in well U.S. $X.X U.S. from $XX.X our commercial to in year-over-year The launch million of million year. quarter headcount for and $XX.X SG&A by the second or down last due in increase compared is

of increase recent reflecting was XXXX, diluted share per count Loss September XX $X.XX September shares, was in Our share our an and X.X 'XX. XX.X shares million primarily of of versus share of impact versus QX $X.XX as offering. the basic million XX,

financing We from will received agreement. subsequently cash planned September slide, us Rhythm following million this As our second additional and cap million, HCR approximately fund an That on closed XXXX. to gives be royalty with $XX a hand prior shoe. offering which $XXX million received quarter on into $XXX my operations sufficient the from tranche I and the indicated in

turn the call David. over to I'll that, back With

David Meeker

Hunter. you, Thank

feel quarter. is is I what So really it. good heard today this you've a great hope about We

executing pediatric execution and XXXX laser-focused LEPR remain we our work POMC now forward, about programs, our BBS weekly and We've our our launch U.S. M&A against in strategic development for talked trials. execution to look progress on update. continued access our next Daybreak only twice market XXXX. That on deficiency BBS now clinical internationally, also ongoing and and continued continued but transformative to for Moving continuing in We priorities on the both to is forward and not hyperchylobesity, opportunity. in

With Q&A. for that, it we'll up open

Operator

of from comes [Operator first Instructions] our from line the Cowen. Nadeau Philip question

Philip Nadeau

Congrats on questions A of commercial us. the for from us progress. couple

a with the is get patients bit the physicians First, help And can the stay you the What you from appeals the with program? more will how compliant do first think to X that mentioned question. InTune X on the progresses? does process? speak ultimately you time Is settle... the likely team script about InTune decrease at That's therapy? to InTune time therapy And question, then to launch that average to reimbursements as Where months. second the do the

Jennifer Chien

Right.

a bit about InTune. little So

needs the program quite built we what of So here overall. was be for was that a customers to customized the

a everything consent. So here with starts patient

like for And reaches patient once also in to pan and Similarly, any we the manager will what once to expectations look education physician moving forward. patient again of meeting for terms moving a receive and forward. a joint or the the outline out our manager to consent, new then introductions there territory just process patient PAN, prescriber, our actually the with educate just is

that prior verifications works specific authorization which out. a understand authorization really every service as payers InTune to for requirements executes required receive, prior filled to be and that benefit exact script that we then is the So stage, needs

out patients we say the of who then a At patient stage, we've that the insurers I this and three some background. have was need had complicated will from to mean insurance primary that figure I insurer where process had our work different there.

or to the lot in need required account. does or prior state, be The ACP we we upfront learn all But of because continue approved for example, that these BBS to complete from that InTune they to because then on the authorization understand of a to the information at to behalf thing that. information were of one out doctor quickly we either all work done the indication. is And The PA for included through what the the denials incomplete his lot not experiences this physician and outlined we do pushes initiates CoverMyMeds, So relevant services have. which documentation. found is a of there's

in just stage upfront necessity an a we So as with medical denials. a of of to once that approval of is letter these just the preauthorization terms again well recommend supplemented as first -- minimize metical FDA

fall we terms PA terms of If in submission, in payer upon and So process every of cetera. status. be off the decision the et who, updated to the denied, exactly submitted keep through is need appeals days then the to we the everybody process two same just on go understand what documents to

reimbursement then just does the once appropriately. bases training And is to approval, team to answer up to sure there the that terms injection appropriate patient be InTune expectations being shipments following touch So like questions the of patient is make initiates the very the the on what is any drug. and therapy, schedules to regular patient sets in titrated

answer So there's questions. days XX a to the first in very just tight any connection, especially

well ACP. really just like script one again, hands-on to try for just to forward. I'll to as to is provide to both approval question, from was the as patient very to which reimbursement personalized as move highlight the what relating it example, average time once experience overall, On a the we So we just look give next

for outlined the stage there of a in lot indication. IMCIVREE launch aren't or One, we're a for policies BBS a where

quicker hope there just approval. in are will terms put that As reimbursement time progresses, in process make are place whole we of policies that the that

example of one is, as launch, including quite going payer, this example, will we're steps, stage for appeals the of it one outline within to first I the to a script process get So bit approved. working took

subsequent that were However, that scripts approved payer days. came within specific to

but the time script parents, initial move will as some the the script specific up. hope similarly, may take get approval forward, for approved, even to So we it for to time be we

Operator

Stifel. question next the question Dae line of Our from from come Gon our will next

Dae Gon

maybe a Hope ago, HO the you that design one progress to One randomized patients, XXX just stands. question behind well. setmelanotide walk congrats but and days XX.X% the from as and The me trial patients. guess, it process on derisking, of With wanted sort is outlined XX.X% you number? commercial get placebo as to landed hear from going XXX the mentioned me. Phase at through to you thought III I XXX powering why of it's after you you that Can me, extremely HO regards guys couple your on thoughts us about on

prescriptions about compare XXX And the talk identified, registry? is can more And the as had much overlap does how the you diagnosed? or XXX that prescriptions, then commercial extension, maybe XXX than that with talked you Cribs question, there with an of previously about how

David Connolly

Yes.

me Let the second. question the take first, and Jennifer HO take

meetings, not patients to and patients knew II, XXX into Phase is we going the we that, the So given be to the likely surprisingly. knew had FDA was prove all the of relatively than you small. that in seen efficacy the efficacy number required patients XXX more was

new that by a number discussion if new indication, indication, safety was agreed negotiated, a evaluation was really driven robust was safety. efficacy. around but that would patients provide a it just of of is and you This that will, upon in this So a not

Jennifer. Next,

Jennifer Chien

outline Relating were I that to prior the that scripts that will the coming were to say of not is terms to in almost of piece one HCPs just known the X/X prescription. Rhythm from XXX scripts,

So just piece that BBS one of to physicians to diagnosing in speaks teams with progress the make around terms the patients. additional continue

relationship the Patient patients of IMCIVREE. that we BBS also to have speaks have with speaks terms the very Association It that with to care and availability health collaborative of over collaborative the helping just the folks It at the inform Marshfield. to providers in very we relationship of

with patients cribs we crib are the the diagnosed. we opportunity that registry expand have again, BBS have say in to just the itself. all to continuing that trying around specific really registry, terms I and of teams general, physicians of that terms once that exact that are just additional in the the In of in overlap don't physicians expand though, of get part are have educating the patients just terms the opportunity already in the folks with that information of understanding patients scripts that will the

Operator

will next Sachs. from question Corinne come Our Jenkins Goldman from of

Corinne Jenkins

the X,XXX BBS, to shared which You've TAM you is compared more X,XXX patients appropriate IMCIVREE and that shared the previously. from is

some give are the what So addressable expanded of launch since that items market? the you the confidence in key

David Meeker

I'll Jennifer then lead can off Yes. Maybe and supplement.

So just soft not as this to and is inform math we there's because lot know, that the that. tends to of a just be diseases, epidemiology we've publications and rare data original

we've we've plus get that been to gotten much X,XXX community, to number of we points kind is larger, information different a triangulate deeper i.e. the of to As believe into the this confidence opportunity. able

again, more. just for the or U.S. used number where, million. XX France European the One said, XXX use the BBS France ones as opportunity of million patients of population, brands patients that just if of for Xx as the France, USD That's and probably patients the BBS X,XXX with costs$XXX Yann number we easily triangulation. is is then of is major number kind in correct you But about the diagnosed

a The tests in really extremely But is they of but other that will diagnosis thing are beginning that. Jennifer blood that's we're test, the interesting play, what's it's and and us part clinical genetic early clinical testing inform. of give diagnosis, to highlighted terms this role a

both to initial X of of instead symptoms a complemented think to patients to patient Their and for earlier And genetics. great or so there's having prior manifestations disease, world, diagnosed by develop we wait a a opportunity for signs in on. be presenting X

that that goes. question, Corrine? But So does we'll answer your see where

Corinne Jenkins

next from Rhythm to XX% prior the that year then what that of kind prescribers might you you continue weren't that it launch the of as targeting Yes, to this have of your expand inform to you known does. learned opportunity. And

Jennifer Chien

background interesting like of in are. of prescribers, think terms in is they just So I the it where the of just terms

XX%, With versus family our would said, from that I probably pediatricians say in terms or had PCPs may that with such. targets, the higher docs of percentage a medicine So some also of it's to or them come obesity certifications target. our and that of interest similar

little bit to a terms IMCIVREE I that prescribers patient. had it's and in of of about how BBS terms be of themselves So they mix the think us. learned It came a in they a could

about inquire IMCIVREE their be also themselves to drug. the and patients the went about could It to because physician learned

that on is the to turn make So a disease we terms clear there of organization, we physicians this drug. try educated patients ground our educating, reach level as a them aware of field efforts terms and of it's in set itself promotion to certain where well on of members as and of non-personal broader the but really in out to have availability

David Meeker

And diseases, they're what's Corrine, quite to primary care said, as because Jennifer rare if to for maybe one experience patient other that and in have example, they're they remarkable, our a population, willing positions, they our attention in give not try. although come a target it thing just

of on an physicians begin those grow, and patients expert interest continue take to truly become they've Some the more area. and to in take

be a possibility will. treater, physician primary the could care So exclude doesn't it that a you if leading

Operator

of Joseph question from Our line Stringer the come from next Needham

Joseph Stringer

from us. A few

first around The patients your identified and than greater one is diagnosed BBS said previously on XXX. the who had

drug? not And on and the far? that eligible getting curious if Has been you're BBS, yet into are compliance launch percentage and you're with understand under expectations for but are below rates question drug? can commercial metrics just in I of line is, therefore those it some now more of patients then that persistence quarter you so second Just provide what or over X early in curious age on just the

David Connolly

Yes. Great... Jennifer?

Jennifer Chien

Sure.

this outlined under don't patients, really the know greater that point, years X we percentage I XXX say So that age. at as of than are will

and not, an greater I patients So of is course, is time. cannot than at to But I focus on percentage will that fruitful get that provide but in on can of to terms how what from that additional diagnosis, this a of one that very the that to be outlining ways perspective. say to patients diagnosis. continuing additional quite I we example get are maybe point outline And point we targeted have XXX our

follow-ups past from field ways. ICD-XX have BBS, facial I've to of mentioned our are as specific of caused just patients well that well a the targeted there terms use learning lot teams, results codes a have for that example but machine as We abnormalities. fact as URO in by as very separate follow-up in retinal is very these issues the our

there many, sort in to teams. U.S. retinal out how deploy the specialists Now we our There more many versus once again, ophthalmologists speaking of are

are educate broader team successful. field So on the our to out we focus go these be non-personal the group retinal specialists may proving and our while and efforts, with promotion

number, just to once opportunity. continuing greater we necessarily So the XXX on again I wouldn't that focus than but are expand

and around metrics of terms compliance. persistence In

HCP appropriate of dose the drug can that I point, this educate On to will to the start walk maintain and terms time just to get internally try and profile on really phase we the say titration spend that through them for so plan patient then they benefits in of initial could a organization lot both the understand the then we of to as therapeutic treatment. an and to see and through how the being just of

So of again, once these quite through same days, to very we're say to hearing the start early it's we that, ability get benefits time, for but happy in patients are I terms that at would the again quite, and experience once the just about.

David Meeker

Joseph? Did that answer the question,

Joseph Stringer

color. Yes, it for Thanks the did.

Operator

Ladenburg. line Our from of next the question Michael Higgins is from

Michael Higgins

from as Congrats the far for progress, question and on Jennifer me in continued David. so A impressive BBS. launch well

a You've answered launch. lot us of coming questions a lot on in given of the our detail,

for a us provide if and launch Curious patient IMCIVREE of BBS on detail lot how can give in the understand count. you going? on patient help Also LEPR, the PCSKX? it's counts POMC, us You

David Meeker

Yes.

updating it I stuck think beginning. we're from not those the that numbers with we

the they're are they think I and number. right informative

treatment on expectation. tens was patients our As of we said,

basically, on number We Michael, have it to tens And We're the of that patients speak is doesn't specifically. BBS going inform reason, to not launch. treatment.

from to that circumstances, larger well. aside if access will, BBS the patients you quite terms or different to get disease as allow that diagnosis metrics to and populations population a fact They're a just the it's overall different treatment come and of in

that's progressing. So

of tens helpful I how and about reimbursement, population go different of And of have, for how somewhat We and Jennifer the the we said, been that's the BBS. good than earlier focus has of predictive is the launch said, that from Other other. feel on to really it, like patients, that. reimbursement but the BBS course, part as here things are going

Michael Higgins

trial long-term that. extension. I The One the if could one, Appreciate that's on hear. in other continuing HO

an point. may those We at patients and see you XX-week update a points. on Do at later we have when know time some

David Meeker

continue we'll I obviously Yes. mean, follow to patients. these

that bit on imagine little So cuts again, weekly, on we the do obviously. depends sort data I earnings of call, that, cuts subsequent when do can data a and don't we

So about in try we time twice fact, year. a them to

So we going that are keep to in following but bottom we will line be We'll closely. yes, XXXX. to work you will update. be It informed, is,

Operator

Our from Hung Stanley. of next question line [Operator is Jeff the Instructions] from Morgan

Unidentified Analyst

on Catherine taking you is for This Jeff, for thank our question.

two. have We

then question study first novo us you one remind from XXXX. you're the on is on all X.X on X providing II, the additional do patients study to see what hoping in de is second of And starting milligrams X in on when they The design obesity, the rationale Could in the at and Phase mind our hypothalamic you III Phase you're color starting milligrams... trial? for or the started

David Meeker

Yes. Yes.

de NOVA a in randomized the predominantly So controlled patients double-blind BBS. trial is trial with

and that of be we'll which major all is two dose PPL be the number since endpoints in population looking a Again, be will the the will with pursued POMC with LEPR of children at primary weekly will adults. looking the we span along, population. since we'll a We that that also small BMI. change in patients be effect have at we'll specifically And and

degree the again, to then that will, uniting So growing this equation. at on to that thoroughly, be on awareness understand health care come aggregate as reinforced. is you hyperphagia I'll again, if that point, allows endpoint, hyperphagia. And hyperphagia more the in is it provider I and of side component to the disease continues population something And we to think this us BMI is the just a and least certain say the

with it of that are quotes shared the think weren't patients articulating Jennifer cherry today. They you picked. I more

those There I the of how I those their an just benefiting the of many in quotes. they're speak said, part and vast level drug. majority hunger quotes. to important like being them are some of mean are improvement And what from of that

So as we'll at that trial be well. in looking that

GI just little a get as it's being of practical the will. part a target at when placebo-controlled were lower being possible. the started a And dose went and little quickly more LEPR. wanted POMC, trial first more little of On that we still bit to do more terms study, target we to dose to tolerability and drug III the year-long cause is know more less the we complaints, people different to there's and slowly, that of greatest to and take their the the We We've Phase four-week which just starting was more a may been lower a urgency to of know, increases is was going get of advantage a risk people aggressive, which The ongoing period, drug. they struggle thing. with for are period patients on as where In slowly as you through going a a at if in therefore, study XX-week the any aggressive dose, the you and dosing, little regimens HL and in that titration slower. experimenting Bardet-Biedl

it, that's practical. So

Operator

the remarks. the Meeker over back further any I'd for like in queue. questions showing call David to turn not closing I'm to any

David Meeker

order to one, forward calls and much again Well, look tuning everyone, next short a up Have earnings quarter in here, for a fourth in. thanks, coming very XXXX. in Two good we our day.

Operator

conference Thank for today's participating. And you this concludes call.

Everyone, may disconnect. You great now a day. have

Rhythm Pharmaceuticals (RYTM) 8 Nov 222022 Q3 Earnings call transcript